文献速递胃肠外科围术期管理与 ERAS

新辅助治疗后食管切除术术后并发症对预后的影响:JCOG1109 III期试验探索性分析

Prognostic Impact of Postoperative Complications After Neoadjuvant Therapy Followed by Esophagectomy for Esophageal Cancer: An Exploratory Analysis of Phase III Trial JCOG1109.
PubMed 文献 · Ann Surg · 2026-03-06

该研究为JCOG1109 III期随机试验的补充分析,评估局部晚期食管癌患者接受新辅助双药、三药化疗或放化疗后行食管切除术,术后并发症(≥2级)对总生存和无进展生存的影响。结果显示并发症在各治疗组均未显著影响OS,且胸腔镜食管切除术可能减弱并发症的预后负面影响。

要点

  • 术后并发症(肺炎、吻合口漏等)在各治疗组均未显著影响总生存。
  • 胸腔镜食管切除术可能减弱并发症对预后的负面影响。
  • 强化新辅助治疗联合微创手术或可降低并发症的预后不良影响。

核心结论

  • 在新辅助治疗后食管切除术患者中,术后并发症与预后无显著关联。
  • 微创食管切除术(如胸腔镜)和强化新辅助治疗可能减少并发症的负面预后影响。

研究设计与样本

  • JCOG1109 III期随机试验的探索性分析,共随机601例,541例接受食管切除术。
  • 患者随机接受新辅助双药化疗(CF)、三药化疗(DCF)或放化疗(CF-RT),随后行开放或胸腔镜食管切除术。

主要发现

  • 术后并发症(≥2级)包括肺炎、吻合口漏、喉返神经麻痹和感染性并发症,在各治疗组均未显著影响OS。
  • 胸腔镜食管切除术对比开放手术,CF、DCF和CF-RT组OS的风险比分别从1.557变为0.802、从1.151变为0.703、从1.548变为1.186。

临床怎么用

  • 对于接受新辅助治疗的食管癌患者,术后并发症不应单独作为预后不良的预测因素。
  • 优先选择胸腔镜等微创食管切除术可能有助于减轻并发症对预后的负面影响。

局限性

  • 本研究为探索性分析,结果需进一步验证。
  • 并发症对预后影响的分析基于特定人群和治疗方法,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Complications after esophagectomy are associated with poor long-term outcomes; however, the prognostic impacts of postoperative complications in patients receiving intensive neoadjuvant chemotherapy remain unclear. This study aimed to investigate the association between postoperative complications and the prognosis of patients receiving intensive neoadjuvant treatment. SUMMARY BACKGROUND DATA: This study is a supplementary analysis of JCOG1109, which is a phase III randomized trial that assessed the efficacy of neoadjuvant doublet chemotherapy (cisplatin plus 5-fluorouracil [CF]), triplet chemotherapy (docetaxel plus cisplatin plus 5-FU [DCF]), and chemoradiotherapy (radiation with CF [CF-RT]) in patients with locally advanced esophageal cancer. METHODS: Patients were randomly assigned to one of the three preoperative therapies, followed by open esophagectomy (OE) or thoracoscopic esophagectomy (TE) with regional lymphadenectomy. Postoperative complications (Grade ≥2) and their impacts on overall survival (OS) and progression-free survival (PFS) were assessed within each arm. RESULTS: A total of 601 patients were randomized (CF/DCF/CF-RT: 199/202/200) and 541 underwent esophagectomy (CF/DCF/CF-RT: 183/181/177) between 2012 and 2018. Postoperative complications, including pneumonia, anastomotic leakage, recurrent laryngeal nerve paralysis, and infectious complications, exhibited no significant impact on OS in any treatment arm. TE introduction appeared to attenuate the prognostic impact of complications: hazard ratios for OS shifted from 1.557 to 0.802, from 1.151 to 0.703, and from 1.548 to 1.186 in the CF, DCF, and CF-RT arms, when comparing OE with TE, respectively. CONCLUSION: In this exploratory analysis of JCOG1109, postoperative complications were not significantly associated with prognosis. Minimally invasive esophagectomy, such as TE and intensified neoadjuvant therapy, may reduce the negative prognostic impact of complications.

来源:Ann Surg,查看原文。版权归原作者所有。

引用

  1. Booka E, Kato K, Ito Y, et al. Prognostic Impact of Postoperative Complications After Neoadjuvant Therapy Followed by Esophagectomy for Esophageal Cancer: An Exploratory Analysis of Phase III Trial JCOG1109. Ann Surg. 2026. PMID: 41787642. doi:10.1097/SLA.0000000000007045

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。